N
At the 2022 AGM during question time a shareholder raised a question and comment regarding whether Brainchip had a flexible pricing policy as this might facilitate getting customers to sign on the dotted line. Both the Chair and the CEO answered in the affirmative that they did have a flexible approach to how they priced the technology to each individual customer.
I have mentioned an Australian company called Nanosonics as an example of a company which has a flexible pricing policy based on a number of different models. The most instructive of how a flexible pricing model can be created to sell product is the model they created with the UK's National Health. To understand how inventive sellers can be to get a sale across the line it is worthwhile following up.
Brainchip is an IP company however it has never tied itself to how it will charge out the IP to any or all customers in fact the former CEO Mr. Dinardo made a strong point that Brainchip would not be disclosing publicly how much it would be charging to maintain flexibility with its customer base. He did suggest that larger customer orders could see a price reduction.
Without changing the business model in anyway Brainchip could agree to amortise the IP licence fee over the life of the product so that the royalty paid would consist of the amount of the royalty plus an amount for the IP licence.
Brainchip makes the point when they are questioned about why such and such a partnership was not announced on the ASX that under the Continous Disclosure Rules unless they can calculate a dollar amount they are not entitled to announce such matters on the ASX.
So lets take Tata Elxsi as an example. Brainchip have released that they have partnered with Tata Elxsi to drive adoption of AKIDA technology in medical and industrial applications.
Brainchip could have contracted with Tata Elxsi on the basis that they will supply the IP and charge 'x' amount royalty and a proportion of the IP licence fee per product produced and sold.
This type of deal would be one which Brainchip would claim does not meet ASX requirements because they do not have any idea how many sales will be made and therefore cannot calculate what the value of the contract with Tata Elxsi is at this point.
When the first sale is made by Tata Elxsi even then Brainchip may not under the terms of the agreement know about the sale until Tata Elxsi accounts to them a sum of money at which point Brainchip would be entitled to then audit to ensure they have not been under or over paid.
These funds being for past events could lead to an announcement about the amount received if it is considered material in nature other wise it could just as we have been told appear in the 4C without attribution.
But ask yourself this question how can Tata Elxsi or any other partner like Microchip suggest they are going to be driving the adoption of AKIDA technology by their customers in the absence of knowledge as to what the product they are selling will cost.
It is ludicrous in the extreme to think that Tata Elxsi will do all the work to design the product and take the customers order without having Brainchip locked in to an agreed price. There is no doubt in my mind that a contract has been signed by Tata Elxsi agreeing terms with Brainchip. It cannot be otherwise.
I do not know the terms of that contract but as I suggest above it could involve amortising the IP licence fee. It could require a million units be sold before the IP licence fee becomes payable and its quantum could be then based upon the value of the future sale book at that time. Brainchip remains an IP company throughout just the terms of payment remain flexible to be agreed by the parties.
My opinion only DYOR
Fact Finder
Brainchip is an IP provider and secrecy of relationships and contract values is very important especially when you are going through development phase.
I still the asx asking questions about value of ip contract receipts was a big issue which hinders company's long term goals.
So that was the time company changed policy and postponed the IP signing until a product ready stage is not coming. So that is why we can see a lot of partners and no IP sale.
We all know the last IP was signed more than 3 years old but still there is no commercial product. So why company should target signing new IPs and then put product development on back burner.
On the other hand it will be a good policy to help partners getting product ready and develop companies ecosystem and gain market confidence and partners' support.
So signing IPs could had delayed the ecosystem development by at least 2-3 years. Signing 4-5 new IPs can help SP but derail company's long term vision.
So I strongly believe partnership developments is helping us getting to our ultimate goal.
My last point is, brainchip is working with other undisclosed companies already under NDAs. So they know better about market and how to grow.
So I will take partners as a good development and another step to our overall goal.